NORTH AMERICA COMPANION ANIMAL DRUGS MARKET ANALYSIS
North America Companion Animal Drugs Market: Key Developments
On January 4, 2022 Zoetis Inc., animal health company announced that the U.S. Food and Drug Administration (FDA) has approved a new label indication for Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks (black-legged or deer ticks). Simparica Trio is approved for dogs eight weeks of age and older weighing 2.8 pounds and greater. Simparica Trio is the first and only combination product demonstrated to prevent infections that may cause Lyme disease by killing deer or black-legged ticks.
On May 16, 2022 Ceva Santé Animale (Ceva), a multinational veterinary pharmaceutical company, acquired the Canadian oral rabies vaccine manufacturer Artemis Technologies, Inc. Artemis, located in, Canada, produces ONRAB, a rabies glycoprotein recombinant oral vaccine licensed for use in striped skunks (Mephitis mephitis) in Canada. The product also had positive field trial use in the USA in wild raccoons and skunks.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
